Abbreviations: AUC, area under the curve; IDS, interval debulking surgery; IP, intraperitoneal; IV, intravenous; NACT, neoadjuvant chemotherapy; NR, not reported; PDS, primary debulking surgery.
a Trials shown in Table 1 .
b All of these trials tested regimens consisting of systemic NACT, followed by IDS (with the goal of maximum cytoreduction), followed by postoperative systemic chemotherapy. Unless otherwise specified, the same regimen was used both as neoadjuvant and postoperatively. In some trials, only patients meeting certain requirements were allowed to have IDS and/or postoperative chemotherapy. OL, open-label; OS, overall survival; PFS, progression-free survival; R, randomized; R0, no macroscopic residual disease; RCT, randomized controlled trial.
a All of these trials tested regimens consisting of systemic NACT (for indicated number of cycles [No. of cycles before IDS]), followed by IDS (with the goal of maximum cytoreduction), followed by postoperative systemic chemotherapy (for the indicated number of cycles [No. of cycles after IDS]). Unless otherwise specified, the same regimen was used both as neoadjuvant and postoperative . In some trials, only patients meeting certain requirements were allowed to have IDS and/or postoperative chemotherapy. In OV21/PETROC, patients were required to have had 3-4 cycles of platinum-based IV NACT (regimen details not reported) followed by optimal IDS (,1 cm); they were randomized after IDS. PFS and OS were measured from randomization. The study was not complete so comparisons of OS were not possible. In OV21/PETROC, patients were required to have had 3-4 cycles of platinum-based IV NACT (regimen details not reported) followed by optimal IDS (,1 cm); they were randomized after IDS. PFS and OS were measured from randomization. The study was not complete so comparisons of OS were not possible. As with a primary debulking procedure, every effort should be made to achieve maximum cytoreduction during an interval debulking procedure. Maximal effort should be made to remove all gross disease in the abdomen, pelvis, and retroperitoneum. Consultation with a gynecologic oncologist is recommended.
• IDS, including completion TAH and BSO with staging, should be performed after #4 cycles of neoadjuvant chemotherapy for women with a response to chemotherapy or stable disease. Alternate timing of surgery has not been prospectively evaluated but may be considered based on individual patient-centered factors.
• Hyperthermic intraperitoneal chemotherapy with cisplatin (100 mg/m 2 ) can be considered at the time of IDS for stage III disease.
• All peritoneal surfaces should be visualized, and any peritoneal surface or adhesion suspicious for harboring metastasis should be selectively excised or biopsied.
• An omentectomy should be performed.
• Suspicious and/or enlarged nodes should be resected, if possible. Removal of lymph nodes noted to have potential metastasis at the time of initial diagnosis should be considered, even if not currently suspicious or enlarged.
• Procedures that may be considered for optimal surgical debulking include bowel resection and/or appendectomy, stripping of the diaphragm or other peritoneal surfaces, splenectomy, partial cystectomy and/or ureteroneocystostomy, partial hepatectomy, partial gastrectomy, cholecystectomy, and/or distal pancreatectomy.
Principles of Surgery: General Considerations for IDS b (OV-A 1 of 4 a )
• It is recommended that a gynecologic oncologist perform the appropriate surgery.
• An open laparotomy including a vertical midline abdominal incision should be used in most patients in whom an interval debulking procedure is planned. • PCI 5 to ,10: 40% vs 37%
• PCI $10: 48% vs 50% Cytoreduction:
• CC-0: 65% vs 55% Severe postoperative morbidity was defined as an adverse event that occurred ,30 days from surgery and resulted in an unplanned admission or in a secondary surgical procedure.
e NACT was allowed if optimal cytoreduction was considered difficult. Patients whose disease progressed during NACT were excluded from the trial. Patients with stage IV distant metastases had supradiaphragmatic lymph node metastasis and/or parenchymal liver metastasis. Criteria for treatment with NACT: (1) high tumor dissemination was observed on initial imaging studies and was assumed to occur under the following conditions: (a) multiple and unresectable extra-abdominal metastases, (b) multiple liver parenchymal metastases or pulmonary metastases, and (c) extensive small bowel/mesenteric root involvement; (2) patients had a poor performance status and high operative risk because of medical comorbidities; or (3) optimal debulking surgery (#1 cm) was unsuitable because of a high tumor burden (Fagotti score Toxicities during the trial intervention or up to 30 days after discontinuation of the intervention.
